Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
BEIJING, China & GOTHENBURG, Sweden — 2025-10-24 — Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infection. The EMA’s ODD is assigned to investigational therapies of life-threatening or […]
Ribo showcases new clinical data from its leading siRNA programs at ESC 2025, underscoring significant progress and achievements in advancing cardiovascular therapies
SuZhou Ribo life science Ltd. Co. and Ribocure Pharmaceuticals AB (Ribo) presented four key scientific findings at the 2025 European Society of Cardiology (ESC) Congress, underscoring significant progress in siRNA-based cardiovascular therapeutics pipeline. Ribo presented results from its ApoC3-silencing RBD5044 program`s Phase 1 clinical trial, which included single and multiple ascending dose studies (n=72 healthy […]
Distinguished Swedish Investors Back Leading Biotech Company in GoCo Health Innovation City to Advance siRNA Therapies
Mölndal, July 2nd 2025 — We are delighted to announce that distinguished Swedish investors Erik Selin and Jacob Torell have joined Ribocure as new shareholders. Through a direct investment totaling USD 33 million, Erik Selin now holds 32.65% of Ribocure shares, while Jacob Torell holds 1%. We thereby warmly welcome Erik Selin as a new […]
Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug
Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd., “Ribo”, is pleased to announce the successful completion of patient recruitment for the Phase 2a clinical trial, utilizing the world’s first and most advanced hemostasis sparing anti-thrombotic siRNA drug, targeting FXI, RBD4059. In less than 10 months since CTA approval of the Phase 2 trial, the […]
Clinical Trials Coming to Health Centers: Unique Collaboration Contributes to the Development of Tomorrow’s Medicines
Ribocure Pharmaceuticals AB and Medtanken Group AB today present a strategic collaboration that allows clinical research to be applied directly in primary care. The collaboration aims to improve healthcare by making clinical trials more accessible to patients in primary care while simultaneously stimulating increased research within this important part of healthcare. The collaboration offers patients […]
Advancing siRNA Drug Discovery and Development with AI
Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully achieved, marking a significant leap forward in our AI-assisted drug development for RNA therapeutics. Leveraging Pheiron’s advanced AI platform, PheironGPS, multiple candidate targets have systematically been profiled by integrating large-scale human multi-omic data with cutting-edge AI analytics. This […]
Ribo Celebrates Rare Disease Day
Today marks an important and exciting milestone for Ribo as we strive to improve treatments for rare diseases. In conjunction with Rare Disease Day February 28th 2025, Ribo is excited to announce that we have received approval to commence a Phase 1 study. This study will investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of our […]
Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA
Recent news highlights that the Factor XI inhibitor space is emerging as the next significant advancement in cardiovascular care, and at Ribo, we are proud to be at the forefront of this development. FXI inhibition has the potential to address a substantial unmet need and to represent a breakthrough in anti-coagulation therapy for millions of […]
Ribo announces the publication of a scientific paper of our liver-targeted siRNA against Factor XI, which is being developed as a potential breakthrough treatment for thrombosis
RBD4059 is a GalNAc-conjugated small-interfering RNA (siRNA) drug independently developed by Suzhou Ribo Life Science. Ltd (Ribo) based on the RIBO-GalSTARTM liver targeting technology platform. RBD4059 achieves antithrombotic effects by silencing the FXI protein expression by RNA interference and thereby blocking the activation of the endogenous coagulation pathway. The results of the current preclinical study […]
First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim
Suzhou Ribo Life Science and Ribocure AB are excited to share that we have achieved a key pre-clinical milestone in our siRNA programs, less than a year into our collaboration with Boehringer Ingelheim. These achievements highlight the strength of Boehringer Ingelheim’s expertise in MASH and validate the power of the Ribo platform and organization. We […]
